Esophagram - Volume 9 / Issue 5

Volume 9, Issue 5 - May 2022

ISDE 2022 is Going Fully Virtual

We were looking forward to holding our congress in beautiful Japan but with current travel restrictions in place and the well-being of our ISDE community in mind, we decided to hold the conference in a virtual format again this year. Therefore, the ISDE 2022 World Congress will now be offered in virtual-only format from September 26 to 28, 2022.

As we are shifting our focus to transition from hybrid to virtual, we can assure you that the experience will be equally exciting, content rich and networking driven.

Thank you for your continued patronage, supportive understanding, and enthusiastic participation in the ISDE 2022 World Congress.

We look forward to your participation in our virtual conference from September 26 to 28, 2022!

Visit ISDE 2022 FAQs

Check the World Congress webpage for updates or join the mailing list

Magnus Nilsson Appointed as Next Journal Co-Editor

ISDE is pleased to announce the appointment of Dr. Magnus Nilsson as the next Co-Editor-in-Chief (surgeon) for the Diseases of the Esophagus (DOTE) Journal. Effective September 29, 2022 Dr. Nilsson will succeed Professor Giovanni Zaninotto who is stepping down during the ISDE 2022 World Congress upon completing his second four-year term.

Dr. Nilsson is a professor of surgery and head of the Division of Upper Abdominal Surgery at Karolinska Institutet and senior consultant surgeon at the Karolinska University Hospital.

Read more details here.

DOTE - Volume 35, Issue 5, May 2022

The latest issue of Diseases of the Esophagus Journal is now available online.

Subscribe to content alerts.

PD-1 Inhibitors in Esophageal Cancer: A Systematic Review of the Oncological Outcomes Associated with PD-1 Blockade and the Evolving Therapeutic Paradigm

DOTE Volume 35, Issue 5:

Editor's Choice - Free Article

Whooley et al assessed the efficacy and safety of PD-1 inhibitors in esophageal and GEJ cancers in a systematic review. This review identified 11 eligible studies reporting outcomes of 3451 patients treated with PD-1 blockade compared with 2286 patients treated with either a placebo or the standard regimen of chemotherapy. Clinically significant improvements in median overall survival have been demonstrated in advanced and metastatic esophageal and GEJ cancer while maintaining acceptable safety profiles. Promising survival data have also recently emerged from PD-1 blockade in the adjuvant setting. PD-1 blockade in esophageal and GEJ cancer has delivered impressive survival benefit while remaining well tolerated.

Evaluation of Inter-user Variability in Indocyanine Green Fluorescence Angiography to Assess Gastric Conduit Perfusion in Esophageal Cancer Surgery

DOTE Volume 35, Issue 5:

Original Article

Indocyanine Green Fluorescence Angiography (ICGFA) has been deployed to assess tissue perfusion. This study assesses variations in operator interpretation of pre-anastomotic ICGFA inflow in the gastric conduit. Utilizing an innovative online interactive multimedia platform. Among users, there were wide variations in dosing (0.05–3 mg/kg) and practice impact. Experts choose levels that preserved more gastric conduit length versus non-experts in all but one video (P = 0.02). Considerable variability exists with ICGFA interpretation and indeed impact. Even adept users may be challenged in specific cases. Standardized training and/or computerized quantitative fluorescence may help better usage.